Medications That Cause Bone Loss: When You Need a DEXA Bone Density Scan

Millions of people in the UK take prescription medications every day for conditions ranging from asthma and acid reflux to epilepsy and breast cancer. What many do not realise is that some of the most widely prescribed drugs can gradually weaken bones, raising the risk of osteoporosis and fracture over months or years of use.

If you are on long-term medication and have never had your bone health assessed, you may be carrying a risk you cannot feel. A bone density DEXA scan is the gold-standard way to measure bone mineral density, detect early loss. Additionally, guide decisions about prevention or treatment before a fracture occurs.

Understanding Medication-Related Bone Loss

This guide explains which medications carry the greatest risk, what the evidence says about each one. Additionally. When to book a bone density scan at our Harley Street clinic.

Why Some Medications Weaken Your Bones

Healthy bone is constantly being remodelled. Specialised cells called osteoblasts build new bone while osteoclasts break down old bone. In a healthy adult, these two processes stay roughly in balance. Certain medications disrupt that balance in different ways.

Some drugs reduce calcium absorption from the gut. This deprives bones of a critical building block. Others accelerate bone resorption by stimulating osteoclast activity. A third group interferes with vitamin D metabolism. This is essential for calcium uptake and bone mineralisation. In some cases, more than one mechanism operates at once, compounding the effect.

The risk is not always obvious. Unlike joint pain or muscle weakness, bone loss produces no symptoms until a fracture occurs. That is why proactive screening with a DEXA scan matters for anyone on a medication known to affect bone density.

Corticosteroids and Bone Health

Oral corticosteroids such as prednisolone, prednisone. Additionally, dexamethasone are the single most common cause of drug-induced osteoporosis. They come as prescriptions for a wide range of conditions including asthma, rheumatoid arthritis, lupus, inflammatory bowel disease. Moreover, organ transplant rejection.

Research shows glucocorticoid use causes secondary osteoporosis in roughly 30 to 50 percent of people who take them chronically. Bone loss begins rapidly. A measurable decline in bone strength within the first three to six months of treatment, primarily driven by increased bone resorption (PMC, Understanding and Managing Corticosteroid-Induced Osteoporosis, 2021).

The risk scales with dose and duration. UK guidelines state that patients on oral glucocorticoids at a dose equivalent to 7.5 mg or more of prednisolone daily for three months or longer should merit attention for a DEXA scan and. There, appropriate, preventive treatment. Higher doses taken continuously can increase vertebral fracture risk by up to 17-fold and hip fracture risk by 7-fold (NOGG Clinical Guideline, 2021).

If your doctor has prescribed a corticosteroid for longer than a few weeks, it is worth asking whether a baseline bone density scan is appropriate, even if you are under 65 and otherwise healthy.

Proton Pump Inhibitors and Fracture Risk

Proton pump inhibitors. Examples include omeprazole, lansoprazole. Additionally, pantoprazole, are among the most frequently prescribed medications in the UK. They serve to manage acid reflux, stomach ulcers. Moreover, gastro-oesophageal reflux disease (GORD). Many patients take them for years.

A large umbrella review found that fracture incidence was 22 percent in PPI users compared to roughly 16 percent in controls, with an overall effect size suggesting a 28 percent increased risk of fracture (PMC, Osseous implications of proton pump inhibitor therapy, 2024). The risk appears to increase with both dose and duration of use. The strongest associations seen in people who have taken PPIs for a year or longer.

UK product data for PPIs note that high-dose or long-duration use (more than one year) may modestly increase the risk of hip, wrist. Furthermore, spine fracture. In particular, in older adults or those with other recognised risk factors.

Interestingly, the fracture risk does not appear to be fully explained by reduced bone mineral density, suggesting that PPIs may affect bone quality or increase fall risk through other pathways. Regardless of the exact mechanism, the clinical implication is the same: long-term PPI users with additional risk factors should discuss bone health screening with their doctor.

SSRIs and Other Medication Risks

Selective serotonin reuptake inhibitors (SSRIs)

Antidepressants in the SSRI class. Examples include fluoxetine, sertraline. Additionally, citalopram, have shown a connection to both lower bone mineral density and higher fracture risk. A meta-analysis of 16 studies found that SSRI users were 1.61 times more likely to experience a fracture than non-users (PMC, The use of antidepressants connects to bone loss, 2022). Serotonin receptors and transporters have emerged on bone cells. Moreover, blocking serotonin reuptake may reduce the proliferation of osteoblast precursor cells. Depression itself and the associated reduction in physical activity may also contribute. So the picture is not straightforward. Still, the signal is strong enough that clinicians should consider bone health in patients on long-term SSRI therapy.

Anti-epileptic drugs

How These Medications Affect Bone Density

Enzyme-inducing anti-epileptic drugs such as phenytoin, carbamazepine. Furthermore, phenobarbital accelerate the metabolism of vitamin D in the liver, converting the active form into inactive metabolites. This leads to reduced calcium absorption and, over time, secondary hyperparathyroidism and bone loss (GOV.UK, Antiepileptics: adverse effects on bone). Both phenytoin and carbamazepine have also proven to directly inhibit osteoblast growth at therapeutic concentrations (PMC, Antiepileptics and Bone Health, 2012). Patients on long-term anti-epileptic treatment should have their vitamin D levels checked and their bone density monitored periodically.

Other medications to be aware of

Several other drug classes carry a recognised bone-loss risk. Long-term heparin use (particularly unfractionated heparin) can reduce bone density. Methotrexate, used for autoimmune conditions and certain cancers, has shown a connection with skeletal toxicity at high cumulative doses. Androgen deprivation therapy for prostate cancer and luteinising hormone-releasing hormone (LHRH) agonists for endometriosis also suppress sex hormones in ways that accelerate bone resorption.

Aromatase Inhibitors and Bone Density

Aromatase inhibitors (AIs) such as letrozole, anastrozole. Additionally, exemestane are a cornerstone of adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. By blocking oestrogen synthesis, they dramatically reduce cancer recurrence. The trade-off accelerates bone loss.

In postmenopausal women on AIs, bone turnover increases and bone mineral density declines at an average rate of 1 to 3 percent per year. In younger women receiving ovarian suppression alongside AI therapy, the loss can be far more severe, averaging 7 to 8 percent per year (British Journal of Medical Practitioners, Practical management of aromatase inhibitor-induced bone loss).

UK consensus guidelines recommend a baseline DEXA scan before starting AI therapy and annual DEXA monitoring throughout treatment. Bisphosphonates, calcium and vitamin D supplementation. Moreover, weight-bearing exercise are the mainstays of prevention (International Osteoporosis Foundation, 2024).

If you are starting or already taking an aromatase inhibitor and have not yet had a bone density assessment, this should come up for discussion with your oncologist or GP as a priority.

When to Request a DEXA Scan

Not every medication user needs an immediate bone scan. However, certain situations warrant a baseline assessment. Clinical guidelines and specialist bodies recommend a DEXA bone density scan if you meet any of the following criteria:

• You have been taking oral corticosteroids (prednisolone, prednisone, or equivalent) at any dose for three months or longer.
• Long-term PPI therapy of 12 months or more (12 months or more) and have additional fracture risk factors such as age over 50, low body weight, a family history of osteoporosis, or a previous fragility fracture.
• Anyone starting an aromatase inhibitor for breast cancer treatment.
• Patients on anti-epileptic medication (particularly phenytoin, carbamazepine, or phenobarbital) for more than two years.
• Those receiving androgen deprivation therapy for prostate cancer or LHRH agonists for endometriosis.
• Long-term SSRI use and have other risk factors for osteoporosis.

A DEXA scan takes around 10 to 15 minutes, uses a very low dose of radiation (less than a chest X-ray). Additionally, provides precise measurements of bone mineral density at the spine and hip. Your results appear as T-scores. This compare your density to a healthy young adult. A T-score of -1.0 or above is normal. between -1.0 and -2.5 indicates osteopenia (early bone thinning). and -2.5 or below falls under the category of as osteoporosis.

Protecting Your Bones While on Medication

Early detection through screening means that protective measures, from lifestyle changes and supplements to prescription treatment, can begin before a fracture occurs. Waiting for symptoms is not an option with bone loss, because the first symptom is often the fracture itself.

Can bone loss from medication reverse?

In many cases, bone density can be partially or fully recovered once the medication is stopped or a bone-protective treatment begins. For corticosteroid-induced bone loss, bisphosphonates demonstrably significantly improve bone mineral density. The key is early detection through DEXA scanning so that treatment can begin before substantial loss has occurred.

Should I stop taking my medication if it causes bone loss?

You should never stop a prescribed medication without consulting your doctor. The condition undergoing treatment often carries greater health risks than the bone loss itself. The goal is to manage bone health alongside your treatment, not to choose between them. Your doctor may adjust the dose, switch to an alternative, or add a bone-protective agent.

How often should I have a DEXA scan if I am on medication that affects bones?

Monitoring Bone Health During Treatment

Key Questions to Ask Your Doctor

For most patients on corticosteroids or aromatase inhibitors, guidelines recommend a baseline scan followed by repeat scanning every one to two years while treatment continues. For other medications, the interval may be longer. Your doctor can advise based on your individual risk profile and results.

Does a short course of steroids affect my bones?

A single short course (one to two weeks) of oral corticosteroids is unlikely to cause measurable bone loss in most people. The risk increases substantially with repeated courses or continuous use beyond three months. If you have needed multiple short courses in the past year, mention this to your doctor when discussing bone health.

Are there medications that protect bones while I take drugs that weaken them?

Yes. Bisphosphonates (such as alendronate and risedronate) doctors commonly prescribe alongside long-term corticosteroids to reduce bone loss. Calcium and vitamin D supplementation merits consideration for nearly all patients at risk. In some cases, newer treatments such as denosumab may merit attention. A DEXA scan helps determine whether protective treatment needs attention and how well it is working.

Book Your DEXA Bone Density Scan

If you are taking any of the medications discussed in this article and have not had your bone density checked, early screening could make a significant difference to your long-term health. A DEXA scan provides objective, precise data that helps you and your doctor make informed decisions about bone protection.

At DEXA London, based at 86 Harley Street in central London, we offer both bone density DEXA scans and body composition DEXA scans. Your results undergo review by Dr Emil Gadimali and returned with a clear, clinician-written report. To book your appointment, call 0207 637 8227 or use our online booking form.

Written by Dr Emil Gadimali